These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 25463273)

  • 21. Nonsense mediated decay factor UPF3B is associated with cMyBP-C haploinsufficiency in hypertrophic cardiomyopathy patients.
    Burkart V; Kowalski K; Disch A; Hilfiker-Kleiner D; Lal S; Dos Remedios C; Perrot A; Zeug A; Ponimaskin E; Kosanke M; Dittrich-Breiholz O; Kraft T; Montag J
    J Mol Cell Cardiol; 2023 Dec; 185():26-37. PubMed ID: 37797718
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Slower Calcium Handling Balances Faster Cross-Bridge Cycling in Human
    Pioner JM; Vitale G; Steczina S; Langione M; Margara F; Santini L; Giardini F; Lazzeri E; Piroddi N; Scellini B; Palandri C; Schuldt M; Spinelli V; Girolami F; Mazzarotto F; van der Velden J; Cerbai E; Tesi C; Olivotto I; Bueno-Orovio A; Sacconi L; Coppini R; Ferrantini C; Regnier M; Poggesi C
    Circ Res; 2023 Mar; 132(5):628-644. PubMed ID: 36744470
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sarcomere mutation-specific expression patterns in human hypertrophic cardiomyopathy.
    Helms AS; Davis FM; Coleman D; Bartolone SN; Glazier AA; Pagani F; Yob JM; Sadayappan S; Pedersen E; Lyons R; Westfall MV; Jones R; Russell MW; Day SM
    Circ Cardiovasc Genet; 2014 Aug; 7(4):434-43. PubMed ID: 25031304
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diltiazem prevents stress-induced contractile deficits in cardiomyocytes, but does not reverse the cardiomyopathy phenotype in Mybpc3-knock-in mice.
    Flenner F; Geertz B; Reischmann-Düsener S; Weinberger F; Eschenhagen T; Carrier L; Friedrich FW
    J Physiol; 2017 Jun; 595(12):3987-3999. PubMed ID: 28090637
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of MYBPC3 loss-of-function mutations preceding hypertrophic cardiomyopathy.
    Helms AS; Tang VT; O'Leary TS; Friedline S; Wauchope M; Arora A; Wasserman AH; Smith ED; Lee LM; Wen XW; Shavit JA; Liu AP; Previs MJ; Day SM
    JCI Insight; 2020 Jan; 5(2):. PubMed ID: 31877118
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characterization of heterozygous and homozygous mouse models with the most common hypertrophic cardiomyopathy mutation MYBPC3
    Hilderink S; Schuldt M; Goebel M; Jansen VJ; Manders E; Moorman S; Dorsch LM; van Steenbeek FG; van der Velden J; Kuster DWD
    J Mol Cell Cardiol; 2023 Dec; 185():65-76. PubMed ID: 37844837
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Activation of Autophagy Ameliorates Cardiomyopathy in
    Singh SR; Zech ATL; Geertz B; Reischmann-Düsener S; Osinska H; Prondzynski M; Krämer E; Meng Q; Redwood C; van der Velden J; Robbins J; Schlossarek S; Carrier L
    Circ Heart Fail; 2017 Oct; 10(10):. PubMed ID: 29021349
    [TBL] [Abstract][Full Text] [Related]  

  • 28. cMyBP-C ablation in human engineered cardiac tissue causes progressive Ca2+-handling abnormalities.
    De Lange WJ; Farrell ET; Hernandez JJ; Stempien A; Kreitzer CR; Jacobs DR; Petty DL; Moss RL; Crone WC; Ralphe JC
    J Gen Physiol; 2023 Apr; 155(4):. PubMed ID: 36893011
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Allelic imbalance and haploinsufficiency in MYBPC3-linked hypertrophic cardiomyopathy.
    Glazier AA; Thompson A; Day SM
    Pflugers Arch; 2019 May; 471(5):781-793. PubMed ID: 30456444
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Myofibroblast-Specific TGFβ Receptor II Signaling in the Fibrotic Response to Cardiac Myosin Binding Protein C-Induced Cardiomyopathy.
    Meng Q; Bhandary B; Bhuiyan MS; James J; Osinska H; Valiente-Alandi I; Shay-Winkler K; Gulick J; Molkentin JD; Blaxall BC; Robbins J
    Circ Res; 2018 Dec; 123(12):1285-1297. PubMed ID: 30566042
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preserved cross-bridge kinetics in human hypertrophic cardiomyopathy patients with MYBPC3 mutations.
    van Dijk SJ; Boontje NM; Heymans MW; Ten Cate FJ; Michels M; Dos Remedios C; Dooijes D; van Slegtenhorst MA; van der Velden J; Stienen GJ
    Pflugers Arch; 2014 Aug; 466(8):1619-33. PubMed ID: 24186209
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Selective phosphorylation of PKA targets after β-adrenergic receptor stimulation impairs myofilament function in Mybpc3-targeted HCM mouse model.
    Najafi A; Sequeira V; Helmes M; Bollen IA; Goebel M; Regan JA; Carrier L; Kuster DW; Van Der Velden J
    Cardiovasc Res; 2016 May; 110(2):200-14. PubMed ID: 26825555
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Deficient cMyBP-C protein expression during cardiomyocyte differentiation underlies human hypertrophic cardiomyopathy cellular phenotypes in disease specific human ES cell derived cardiomyocytes.
    Monteiro da Rocha A; Guerrero-Serna G; Helms A; Luzod C; Mironov S; Russell M; Jalife J; Day SM; Smith GD; Herron TJ
    J Mol Cell Cardiol; 2016 Oct; 99():197-206. PubMed ID: 27620334
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phosphomimetic cardiac myosin-binding protein C partially rescues a cardiomyopathy phenotype in murine engineered heart tissue.
    Dutsch A; Wijnker PJM; Schlossarek S; Friedrich FW; Krämer E; Braren I; Hirt MN; Brenière-Letuffe D; Rhoden A; Mannhardt I; Eschenhagen T; Carrier L; Mearini G
    Sci Rep; 2019 Dec; 9(1):18152. PubMed ID: 31796859
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hypertrophic cardiomyopathy mutations in
    Toepfer CN; Wakimoto H; Garfinkel AC; McDonough B; Liao D; Jiang J; Tai AC; Gorham JM; Lunde IG; Lun M; Lynch TL; McNamara JW; Sadayappan S; Redwood CS; Watkins HC; Seidman JG; Seidman CE
    Sci Transl Med; 2019 Jan; 11(476):. PubMed ID: 30674652
    [TBL] [Abstract][Full Text] [Related]  

  • 36. How do MYBPC3 mutations cause hypertrophic cardiomyopathy?
    Marston S; Copeland O; Gehmlich K; Schlossarek S; Carrier L
    J Muscle Res Cell Motil; 2012 May; 33(1):75-80. PubMed ID: 22057632
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recovery of left ventricular function following in vivo reexpression of cardiac myosin binding protein C.
    Giles J; Patel JR; Miller A; Iverson E; Fitzsimons D; Moss RL
    J Gen Physiol; 2019 Jan; 151(1):77-89. PubMed ID: 30573635
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HSC70 is a chaperone for wild-type and mutant cardiac myosin binding protein C.
    Glazier AA; Hafeez N; Mellacheruvu D; Basrur V; Nesvizhskii AI; Lee LM; Shao H; Tang V; Yob JM; Gestwicki JE; Helms AS; Day SM
    JCI Insight; 2018 Jun; 3(11):. PubMed ID: 29875314
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ablation of cardiac myosin binding protein-C disrupts the super-relaxed state of myosin in murine cardiomyocytes.
    McNamara JW; Li A; Smith NJ; Lal S; Graham RM; Kooiker KB; van Dijk SJ; Remedios CGD; Harris SP; Cooke R
    J Mol Cell Cardiol; 2016 May; 94():65-71. PubMed ID: 27021517
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MicroRNA transcriptome profiling in cardiac tissue of hypertrophic cardiomyopathy patients with MYBPC3 mutations.
    Kuster DW; Mulders J; Ten Cate FJ; Michels M; Dos Remedios CG; da Costa Martins PA; van der Velden J; Oudejans CB
    J Mol Cell Cardiol; 2013 Dec; 65():59-66. PubMed ID: 24083979
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.